Back to discover
Drug

Ethionamide

In clinical development
ClassEnoyl-[acyl-carrier-protein] reductase inhibitorEmerging researchLate-stage development
Also known as 2-ethyl-4-thiopyridylamide, 2-ethylthioisonicotinamide, ETH, ETP+11 more

2-ethyl-4-thiopyridylamide, 2-ethylthioisonicotinamide, ETH, ETP, Ethylisothiamide, Etionamid, Etionamida, Etionamide, Etioniamid, Trecator, Trecator-SC, Ethinamide, Ethioniamide, Ethyonomide, Ethionamidum.

RxNorm4127ChEMBLCHEMBL1441ATCJ04AD03UNIIOAY8ORS3CQ
1
Research papers
1
Active clinical trials
inhA
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Clinical trial2025-10-07Results expected Q4 2027 · ClinicalTrials.gov

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Clinical trial2024-04-16Completed · ClinicalTrials.gov

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

Research2024-03-28BMJ global health

Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial

Clinical trial2021-08-30Completed · ClinicalTrials.gov

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Clinical trial1998-10-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ethionamide
Aliases & brands
2-ethyl-4-thiopyridylamide2-ethylthioisonicotinamideETHETPEthylisothiamideEtionamidEtionamidaEtionamideEtioniamidTrecatorTrecator-SCEthinamideEthioniamideEthyonomideEthionamidum
RxNorm CUI
4127
ChEMBL ID
CHEMBL1441
ATC codes
J04AD03
UNII
OAY8ORS3CQ
Primary mechanism
Enoyl-[acyl-carrier-protein] reductase inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Enoyl-[acyl-carrier-protein] reductase [NADH]
inhA · P9WGR1
INHIBITOREnoyl-[acyl-carrier-protein] reductase inhibitor

Clinical trials

4 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
4
registered trials across all phases
LATEST COMPLETION 2024
1
Active studies
1
Recruiting
2
Late-stage (III+)
3
Completed
PHASE DISTRIBUTIONn = 4
Phase 22Phase 2 / 31Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial

CompletedPH II/IIIUniversity of Cape Townn=1542021

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

CompletedPH IITASK Applied Sciencen=1052024

Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial

CompletedPH II/IIIUniversity of Cape Townn=1542021

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

CompletedN/ANational Institute of Allergy and Infectious Diseases (NIAID)n=5251998

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Antitubercular Agents1Tuberculosis, Multidrug-Resistant1
Journals, researchers & institutions
Top journals
  • BMJ global health1
Leading researchers
  • Alam SMM1
  • Basilio RP1
  • Dixit A1
  • Farhat MR1
  • Freschi L1
  • Gröschel MI1
  • Ismail N1
  • Kamal SMM1
Leading institutions
free-text, unnormalised
  • Boston Children's Hospital1
  • Center for Computational Biomedicine1
  • Clinical Microbiology and Infectious Diseases1
  • Dana-Farber Cancer Institute1
  • Harvard Medical School1
  • Massachusetts General Hospital1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Isoniazid

Acts on the same molecular target as Ethionamide, with an overlapping disease area.

Shared target1 shared disease1 shared paper
Rifampin

Studied across the same disease area as Ethionamide in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials